October 30,2007
Grassley delves further into FDA review of foreign-made pharmaceuticals
WASHINGTON — Sen. Chuck Grassley is following up on his initial inquiry of the Food and Drug Administration regarding its work to ensure the safety of foreign-made pharmaceutical ingredients and medicines with a series of questions about foreign inspection funding, FDA registration of foreign plants, newly emerging exporters of pharmaceuticals, and weaknesses in the foreign inspection process.
The text of the letter he sent today to the FDA Commissioner follows here, along with the text of his August letter.
###
Next Article Previous Article
Recent News
- Wyden Statement on New Biden-Harris Administration Affordable Housing Initiative
- Wyden Hearing Statement on Tax Court Nominations
- Wyden, Crapo Lead Introduction of Bipartisan Bill to Improve Unemployment Insurance
- Wyden Renews Call for PBM Reforms Needed to Lower Drug Prices and Increase Access Following New FTC Report
- Wyden and Whitehouse Ask Attorney General to Appoint Special Counsel to Investigate Potential Ethics and Tax Law Violations by Justice Clarence Thomas and His Benefactors